TC-A101
/ TCRCure, Xinqiao Hospital
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
October 23, 2024
Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors
(clinicaltrials.gov)
- P1/2 | N=20 | Recruiting | Sponsor: Xinqiao Hospital of Chongqing | Suspended ➔ Recruiting
CAR T-Cell Therapy • Enrollment open • Metastases • Oncology • Solid Tumor • MSLN
October 02, 2024
Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors
(clinicaltrials.gov)
- P1/2 | N=20 | Suspended | Sponsor: Xinqiao Hospital of Chongqing | Recruiting ➔ Suspended
Trial suspension • Oncology • Solid Tumor • MSLN
August 12, 2024
Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors
(clinicaltrials.gov)
- P1/2 | N=20 | Recruiting | Sponsor: Xinqiao Hospital of Chongqing | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2023 ➔ May 2025 | Trial primary completion date: Dec 2022 ➔ Dec 2024
CAR T-Cell Therapy • Enrollment open • Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor • MSLN
October 06, 2022
Anti-ALPP CAR-T Cell Immunotherapy for Ovarian and Endometrial Cancer
(SITC 2022)
- "Conclusions The preclinical findings reported here indicate that ALPP could be a good target and anti-ALPP CAR-T cell immunotherapy is potentially safe and efficacious against female reproductive cancers expressing ALPP. Ethics Approval All in vivo experiments in this study were conducted according to guidelines under a protocol approved by Mispro Biotech Services Institutional Animal Care and Use Committee."
CAR T-Cell Therapy • IO biomarker • Endometrial Cancer • Oncology • Ovarian Cancer • Solid Tumor • ALPP
July 28, 2022
First-in-human anti-ALPP CAR-T cell immunotherapy for ovarian and endometrial cancer
(ESMO 2022)
- P1/2 | "We observed objective tumor regression in two of these three patients, with one patient reaching the threshold of partial response. Conclusions The preclinical and initial clinical findings reported here indicate that TC-A101 T cell immunotherapy is safe and potentially efficacious against female reproductive cancers expressing ALPP."
CAR T-Cell Therapy • IO biomarker • P1 data • Endometrial Cancer • Oncology • Ovarian Cancer • Solid Tumor • ALPP
1 to 5
Of
5
Go to page
1